Barclays PLC Acquires 61,035 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI)

Barclays PLC raised its holdings in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 64.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 156,267 shares of the company's stock after purchasing an additional 61,035 shares during the period. Barclays PLC owned 0.20% of Trevi Therapeutics worth $643,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of TRVI. JPMorgan Chase & Co. lifted its holdings in shares of Trevi Therapeutics by 220.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 100,517 shares of the company's stock valued at $336,000 after purchasing an additional 69,167 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Trevi Therapeutics by 14.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 173,063 shares of the company's stock worth $713,000 after acquiring an additional 22,145 shares in the last quarter. Renaissance Technologies LLC raised its holdings in shares of Trevi Therapeutics by 42.0% during the fourth quarter. Renaissance Technologies LLC now owns 100,400 shares of the company's stock worth $414,000 after acquiring an additional 29,700 shares during the period. American Century Companies Inc. boosted its stake in Trevi Therapeutics by 44.7% in the 4th quarter. American Century Companies Inc. now owns 78,143 shares of the company's stock worth $322,000 after purchasing an additional 24,153 shares during the period. Finally, Raymond James Financial Inc. bought a new position in Trevi Therapeutics during the 4th quarter worth about $49,000. Institutional investors own 95.76% of the company's stock.

Trevi Therapeutics Stock Performance

Shares of TRVI stock remained flat at $6.60 during trading hours on Friday. 1,429,963 shares of the stock traded hands, compared to its average volume of 1,168,524. The firm has a 50 day moving average price of $6.15 and a 200 day moving average price of $4.53. Trevi Therapeutics, Inc. has a 12-month low of $2.30 and a 12-month high of $7.39. The stock has a market cap of $659.29 million, a PE ratio of -15.00 and a beta of 0.62.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.04. Equities analysts forecast that Trevi Therapeutics, Inc. will post -0.49 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Trevi Therapeutics news, insider Farrell Simon sold 81,313 shares of the company's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $6.75, for a total transaction of $548,862.75. Following the transaction, the insider now owns 76,900 shares in the company, valued at approximately $519,075. This represents a 51.39 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Jennifer L. Good sold 5,263 shares of Trevi Therapeutics stock in a transaction dated Friday, March 21st. The shares were sold at an average price of $6.58, for a total value of $34,630.54. Following the transaction, the chief executive officer now owns 213,313 shares of the company's stock, valued at $1,403,599.54. This trade represents a 2.41 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 24.37% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have commented on the company. Raymond James upgraded Trevi Therapeutics from an "outperform" rating to a "strong-buy" rating and boosted their target price for the company from $9.00 to $29.00 in a research note on Monday, March 10th. Oppenheimer raised their target price on shares of Trevi Therapeutics from $12.00 to $20.00 and gave the company an "outperform" rating in a research report on Tuesday, March 11th. Needham & Company LLC restated a "buy" rating and set a $24.00 price objective on shares of Trevi Therapeutics in a research note on Tuesday, April 8th. D. Boral Capital reaffirmed a "buy" rating and issued a $21.00 target price on shares of Trevi Therapeutics in a research report on Wednesday, March 19th. Finally, B. Riley reissued a "buy" rating and set a $20.00 price target (up from $11.00) on shares of Trevi Therapeutics in a research report on Wednesday, March 19th. Seven equities research analysts have rated the stock with a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $17.56.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.